| Title |
Author |
Type |
Date |
Words |
| Bio2 Technologies Inc wins US FDA approval to evaluate Vitrium as a cervical interbody fusion device under IDE clinical study. |
|
|
Nov 14, 2018 |
194 |
| Bio2 Technologies Inc wins US FDA approval to evaluate Vitrium as a cervical interbody fusion device under IDE clinical study. |
|
|
Nov 14, 2018 |
198 |
| PolyPid passes US FDA clearance to launch clinical trial of D-PLEX[100] for the prevention of sternal wound infection. |
|
|
Nov 13, 2018 |
233 |
| Clinical Trial Offers Hope for HIV Cure. |
|
|
Nov 13, 2018 |
150 |
| Aravive: AVB-S6-500 met endpoints in Phase 1 clinical trial. |
|
|
Nov 13, 2018 |
375 |
| Statistical Consultations And Analyzes In Clinical Research (sweden-vnersborg: Statistical Services). |
|
|
Nov 13, 2018 |
134 |
| PolyPid passes US FDA clearance to launch clinical trial of D-PLEX[100] for the prevention of sternal wound infection. |
|
Clinical report |
Nov 13, 2018 |
237 |
| PharmaCyte Biotech Selects Medpace as CRO for Its Clinical Trial in Pancreatic Cancer. |
|
|
Nov 12, 2018 |
676 |
| Concert Pharmaceuticals reports 'positive' CTP-543 results in Phase 2a trial. |
|
|
Nov 12, 2018 |
370 |
| Akcea, Ionis say Phase 2 study in patients with elevated Lp(a) met endpoints. |
|
Clinical report |
Nov 12, 2018 |
287 |
| Ophthotech announces results from Phase 2a safety trial of Zimura. |
|
Financial report |
Nov 12, 2018 |
749 |
| Madrigal Pharmaceuticals presents Phase 2 results for MGL-3196 in NASH. |
|
|
Nov 12, 2018 |
113 |
| United States : Dr. Jill Biden, National Minority Quality Forum, Global Sponsors and CROs Discuss the Future of Healthcare and Clinical Research at Medidata NEXT NYC 2018. |
|
|
Nov 12, 2018 |
278 |
| United States : PharmaCyte Biotech Selects Medpace as CRO for Its Clinical Trial in Pancreatic Cancer. |
|
|
Nov 12, 2018 |
494 |
| Visterra commences VIS649 phase one clinical study. |
|
Clinical report |
Nov 12, 2018 |
195 |
| Visterra commences VIS649 phase one clinical study. |
|
Clinical report |
Nov 12, 2018 |
191 |
| Monitoring Clinical Studies. |
|
Clinical report |
Nov 11, 2018 |
281 |
| Eidos Therapeutics announces positive Phase 2 data for AG10. |
|
|
Nov 11, 2018 |
308 |
| Fate Therapeutics announces dose-escalation clinical data of FATE-NK100. |
|
|
Nov 11, 2018 |
512 |
| Enyo Pharma Completes Phase Ib with Its FXR Agonist EYP001 and the Start of Phase II Studies in Two Indications, NASH and HBV. |
|
|
Nov 9, 2018 |
723 |
| Alpine says 'on track' to initiate human clinical trials of ALPN-202 in 4Q19. |
|
|
Nov 9, 2018 |
380 |
| Gilead presents Phase 2 data on investigational FXR agonist GS-9674. |
|
|
Nov 9, 2018 |
553 |
| Spring Bank Pharmaceuticals presents additional Phase 2 ACHIEVE results at AASLD. |
|
|
Nov 9, 2018 |
293 |
| Mirati Therapeutics presents data from Phase 2 trial of sitravatinib/nivolumab. |
|
|
Nov 9, 2018 |
262 |
| Mirati Therapeutics presents preliminary data from Phase 2 trial of sitravatinib. |
|
|
Nov 9, 2018 |
194 |
| Mirati Therapeutics presents data from Phase 2 trial of mocetinostat combination. |
|
|
Nov 9, 2018 |
215 |
| X4 Pharmaceuticals Presents Clinical Data Demonstrating Single Agent X4P-001-IO Enhances Tumor Immunity through CXCR4 Antagonism. |
|
|
Nov 9, 2018 |
627 |
| Sensei Biotherapeutics Presents Clinical Trial Data Demonstrating SNS-301 Induces Rapid and Robust Antigen-specific Immune Responses. |
|
|
Nov 9, 2018 |
743 |
| Reagents, Control And Consumables For Analyzers Of A Clinical Diagnostic Laboratory, Diagnostic Kits For General Clinical Research Of A Health Care Institution 4th City Childrens Clinical Polyclinic. |
|
|
Nov 8, 2018 |
149 |
| Themis Bioscience Publishes Compelling Phase 2 Results for Lead Vaccine Candidate against Chikungunya Fever in The Lancet. |
|
|
Nov 8, 2018 |
488 |
| InflaRx completes enrollment in IFX-1 Phase IIb clinical trial. |
|
Clinical report |
Nov 8, 2018 |
157 |
| Urovant Sciences completes patient enrollment in vibegron Phase 3 pivotal trial. |
|
Clinical report |
Nov 8, 2018 |
166 |
| BeiGene initiates head-to-head Phase 3 Zanubrutinib trial. |
|
|
Nov 7, 2018 |
267 |
| Rocket Pharmaceuticals announces FDA clearance of IND application for RP-L102. |
|
|
Nov 7, 2018 |
130 |
| Endo announces 'positive' results from Phase 3 studies of CCH. |
|
|
Nov 7, 2018 |
118 |
| Aridis Pharmaceuticals' AR-301 Phase 1/2a data featured in publication. |
|
|
Nov 7, 2018 |
179 |
| OncoSec doses first patient in KEYNOTE-890 Phase 2 clinical trial. |
|
|
Nov 7, 2018 |
117 |
| BD announces clinical trial data for Lutonix IDE level 1 for BTK indication. |
|
Clinical report |
Nov 7, 2018 |
236 |
| Voyager told by FDA Phase 2 trial is an early phase exploratory study. |
|
|
Nov 7, 2018 |
186 |
| Genkyotex's GKT831 succeeds in a phase two trial in primary biliary cholangitis. |
|
|
Nov 7, 2018 |
174 |
| Bristol-Myers Squibb establishes clinical trial collaboration with Infinity Pharmaceuticals. |
|
|
Nov 7, 2018 |
207 |
| Genkyotex's GKT831 succeeds in a phase two trial in primary biliary cholangitis. |
|
|
Nov 7, 2018 |
170 |
| Bristol-Myers Squibb establishes clinical trial collaboration with Infinity Pharmaceuticals. |
|
|
Nov 7, 2018 |
203 |
| Purdue Pharma announces enrolment of first patient Phase 1 investigator-initiated clinical trial of tinostamustine treatment for glioblastoma. |
|
|
Nov 6, 2018 |
257 |
| FLX Bio Inks Clinical Trial Collaboration Agreement with Merck for Ongoing Phase 1/2 Study of FLX475. |
|
|
Nov 6, 2018 |
380 |
| Purdue Pharma announces enrolment of first patient Phase 1 investigator-initiated clinical trial of tinostamustine treatment for glioblastoma. |
|
|
Nov 6, 2018 |
253 |
| Oncobiologics advances ONS-5010 into wet AMD clinical trial. |
|
|
Nov 6, 2018 |
154 |
| United States : Phase 1b/2 Data of Durvalumab Plus Danvatirsen Presented at European Society for Medical Oncology. |
|
|
Nov 6, 2018 |
403 |
| Acesion Pharma reports positive results from Phase 1 clinical trial of lead compound in cardioversion, AP30663. |
|
|
Nov 5, 2018 |
234 |
| Acesion Pharma reports positive results from Phase 1 clinical trial of lead compound in cardioversion, AP30663. |
|
|
Nov 5, 2018 |
230 |
| Opiant Pharmaceuticals announces LPLV for Phase 2 OPNT001 trial. |
|
Clinical report |
Nov 5, 2018 |
111 |
| Clearside Biomedical says Sapphire Phase 3 study did not meet primary endpoint. |
|
|
Nov 5, 2018 |
163 |
| CohBar: Phase 1 CB4211 study 'temporarily suspended' to address site reactions. |
|
|
Nov 5, 2018 |
236 |
| United States : Physician at Hackensack University Medical Center Leads the first U.S. Clinical Trial of a Promising New Drug to TreatCharcot-Marie-Tooth Disease. |
|
|
Nov 5, 2018 |
430 |
| Verona Pharma completes patient enrolment for phase two trial of RPL554. |
|
|
Nov 5, 2018 |
256 |
| Bavarian Nordic announces first patent dosed and initiation of clinical trial evaluating the combination therapy of CV301 and Durvalumab in metastatic colorectal and pancreatic cancers. |
|
|
Nov 5, 2018 |
421 |
| Verona Pharma completes patient enrolment for phase two trial of RPL554. |
|
|
Nov 5, 2018 |
252 |
| Bavarian Nordic announces first patent dosed and initiation of clinical trial evaluating the combination therapy of CV301 and Durvalumab in metastatic colorectal and pancreatic cancers. |
|
|
Nov 5, 2018 |
417 |
| Lipocine Inc concludes enrolment under the ambulatory blood pressure clinical study of TLANDO. |
|
Clinical report |
Nov 2, 2018 |
217 |
| Lipocine Inc concludes enrolment under the ambulatory blood pressure clinical study of TLANDO. |
|
Clinical report |
Nov 2, 2018 |
213 |
| Cyclacel, MD Anderson enter into clinical studies partnership. |
|
|
Nov 2, 2018 |
232 |
| Delayed Start Protocol with Gonadotropin-releasing Hormone Antagonist in Poor Responders Undergoing In Vitro Fertilization: A Randomized, Double-blinded, Clinical Trial. |
Zarei, Afsoon; Parsanezhad, Mohammad Ebrahim; Kutenaei, Maryam Azizi; Jahromi, Bahia Namavar; Bakhsh |
|
Nov 1, 2018 |
4110 |
| Sublingual Immunotherapy Tablets Relieve Symptoms in Adults with Allergic Rhinitis: A Meta-analysis of Randomized Clinical Trials. |
Li, Yi; Yu, Shi-Yuan; Tang, Rui; Zhao, Zuo-Tao; Sun, Jin-Lyu |
Report |
Nov 1, 2018 |
4235 |
| Comment to 'Recurrent Glioblastoma Treated with Recombinant Poliovirus'. |
Wang, Peng; Chen, Guang-Zhong |
Report |
Nov 1, 2018 |
708 |
| US FDA grants approval to Sandoz's Hyrimoz. |
|
|
Nov 1, 2018 |
136 |
| US FDA grants approval to Sandoz's Hyrimoz. |
|
|
Nov 1, 2018 |
132 |
| Senhwa Biosciences wins US FDA's approval for Silmitasertib's IND for the treatment of basal cell carcinoma. |
|
|
Nov 1, 2018 |
277 |
| Senhwa Biosciences wins US FDA's approval for Silmitasertib's IND for the treatment of basal cell carcinoma. |
|
|
Nov 1, 2018 |
273 |
| Adagene treats first patient with ADG-106 in the US & announces ADG-106 IND filing in China. |
|
|
Nov 1, 2018 |
185 |
| Adagene treats first patient with ADG-106 in the US & announces ADG-106 IND filing in China. |
|
|
Nov 1, 2018 |
181 |
| Constellation Pharmaceuticals receives fast track designation for CPI-0610. |
|
|
Nov 1, 2018 |
156 |
| Novan data from SB206 Phase 2 trial published in Journal of Drugs in Dermatology. |
|
|
Nov 1, 2018 |
158 |
| Karyopharm to present results of clinical studies investigating selinexor. |
|
Clinical report |
Nov 1, 2018 |
346 |
| Histogenics, FDA continue to discuss NeoCart Phase 3 data, regulatory pathway. |
|
|
Nov 1, 2018 |
126 |
| Comparison of frequency of post-obturation pain of single versus multiple visit root canal treatment of necrotic teeth with infected root canals. A Randomized Controlled Trial. |
|
Clinical report |
Oct 31, 2018 |
3113 |
| Innovent Announces First Patient Dosed in a Phase I Clinical Trial of Anti-CTLA-4 Monoclonal Antibody. |
|
|
Oct 31, 2018 |
286 |
| Horizon Pharma Presents Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab. |
|
|
Oct 31, 2018 |
680 |
| Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011. |
|
|
Oct 31, 2018 |
689 |
| Acadia reports Phase 2 CLARITY trial in MDD met primary endpoint. |
|
|
Oct 31, 2018 |
252 |
| Tonix Pharmaceuticals announces design for Phase 3 study of Tonmya for PTSD. |
|
|
Oct 31, 2018 |
256 |
| Savara completes target enrollment for OPTIMA trial. |
|
|
Oct 31, 2018 |
105 |
| CStone doses first patient with solid tumour under Phase I study of MEK inhibitor CS3006. |
|
|
Oct 30, 2018 |
246 |
| CStone doses first patient with solid tumour under Phase I study of MEK inhibitor CS3006. |
|
|
Oct 30, 2018 |
242 |
| Humacyte Starts Phase II Vascular Trauma Trial. |
|
|
Oct 30, 2018 |
504 |
| Anavex announces first patient enrolled in Phase 2 ANAVEX2-73 study for PDD. |
|
Clinical report |
Oct 30, 2018 |
112 |
| Mustang Bio announces initiation of Phase 1 in HER2-positive breast cancer. |
|
|
Oct 30, 2018 |
228 |
| CymaBay initiates Phase 3 ENHANCE trial for treatment of PBC. |
|
|
Oct 30, 2018 |
117 |
| Japan : Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimers Disease (CTAD). |
|
|
Oct 30, 2018 |
258 |
| Japan : Eisai Presents New Data on Lemborexant for Treatment of Irregular Sleep-wake Rhythm Disorder in Patients With Alzheimers Disease at the 11th Clinical Trials in Alzheimers Disease Conference. |
|
Conference news |
Oct 30, 2018 |
709 |
| Japan : Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimers Disease at the 2018 Clinical Trials on Alzheimers Disease (Ctad) Conference. |
|
Clinical report |
Oct 30, 2018 |
335 |
| Generex Biotechnology Makes IND Filing for a Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda) for the Treatment of Triple-Negative Breast Cancer. |
|
|
Oct 30, 2018 |
440 |
| Bristol-Myers Squibb doses first patient in clinical trial of BMS-986179. |
|
|
Oct 29, 2018 |
195 |
| Daiichi Sankyo, Merck and Pfizer sign clinical trial collaboration agreement. |
|
|
Oct 29, 2018 |
262 |
| Nordic Nanovector selects first US clinical trial site for Betalutin Lymphoma drug. |
|
|
Oct 29, 2018 |
260 |
| Bristol-Myers Squibb doses first patient in clinical trial of BMS-986179. |
|
|
Oct 29, 2018 |
191 |
| Daiichi Sankyo, Merck and Pfizer sign clinical trial collaboration agreement. |
|
|
Oct 29, 2018 |
258 |
| Nordic Nanovector selects first US clinical trial site for Betalutin Lymphoma drug. |
|
|
Oct 29, 2018 |
256 |
| AC Immune's partner Life molecular presents data from 18F-PI-2620 clinical study. |
|
Clinical report |
Oct 29, 2018 |
109 |
| Melinta Therapeutics announces results from Phase 3 Baxdela trial. |
|
|
Oct 29, 2018 |
255 |
| Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at CTAD. |
|
|
Oct 29, 2018 |
1237 |
| GenSight Biologics Enrolls First Subject in First-in-man PIONEER Phase I/II Clinical Trial of GS030 Combining Gene Therapy and Optogenetics for the Treatment of Retinitis Pigmentosa. |
|
|
Oct 29, 2018 |
885 |
| Spark Therapeutics presents analyses from Phase 3 trial of Luxturna. |
|
|
Oct 29, 2018 |
219 |
| Esperion announces positive top-line results from Phase 3 Bempedoic Acid study. |
|
Clinical report |
Oct 28, 2018 |
324 |
| United States : Demonstrated a Significant Improvement in Progression-Free Survival (PFS) Compared with Observation in a Randomized Study in Patients with Smoldering Multiple Myeloma. |
|
|
Oct 27, 2018 |
212 |
| Jit Automated Clinical Trial Pharmacy Solution. |
|
|
Oct 27, 2018 |
505 |
| Nordic opens first clinical site in the US for the enrollment of patients under the pivotal PARADIGME trial. |
|
|
Oct 26, 2018 |
268 |
| Roche's Xofluza granted FDA approval. |
|
|
Oct 26, 2018 |
175 |
| Biogen, Eisai present Phase 1b aducanumab data at CTAD. |
|
|
Oct 26, 2018 |
158 |
| Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimer's Disease. |
|
Clinical report |
Oct 26, 2018 |
2126 |
| Novaliq Touts Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Disease. |
|
|
Oct 26, 2018 |
284 |
| Consumables For Hematological And Clinical Trials. |
|
|
Oct 26, 2018 |
162 |
| Cortexyme Touts Phase 1 Data Demonstrating COR388 is Safe and Well Tolerated in Healthy Older Volunteers and Alzheimer's Patients. |
|
|
Oct 26, 2018 |
922 |
| Oyster Point Touts Positive Results from Two Separate Phase 2b Clinical Trials of the company's Investigational Treatments for Dry Eye Disease. |
|
|
Oct 26, 2018 |
241 |
| BioArctic presents additional BAN2401 phase 2b study results in early Alzheimer's disease at the 2018 CTAD conference in Barcelona. |
|
Conference news |
Oct 26, 2018 |
366 |
| BioArctic presents additional BAN2401 phase 2b study results in early Alzheimer's disease at the 2018 CTAD conference in Barcelona. |
|
Conference news |
Oct 26, 2018 |
367 |
| BioArctic presents additional BAN2401 phase 2b study results in early Alzheimer's disease at the 2018 CTAD conference in Barcelona. |
|
Conference news |
Oct 26, 2018 |
362 |
| Nordic opens first clinical site in the US for the enrollment of patients under the pivotal PARADIGME trial. |
|
|
Oct 26, 2018 |
272 |
| Orion and Bayer announce completion of phase III trial of darolutamide; primary end point met. |
|
|
Oct 25, 2018 |
460 |
| Green Valley Pharmaceutical updates Phase 3 clinical trial of GV-971 at 11th Clinical Trials on Alzheimer's Disease Conference in Barcelona, Spain. |
|
Conference news |
Oct 25, 2018 |
262 |
| Orion and Bayer announce completion of phase III trial of darolutamide; primary end point met. |
|
|
Oct 25, 2018 |
461 |
| Orion and Bayer announce completion of phase III trial of darolutamide; primary end point met. |
|
|
Oct 25, 2018 |
456 |
| Green Valley Pharmaceutical updates Phase 3 clinical trial of GV-971 at 11th Clinical Trials on Alzheimer's Disease Conference in Barcelona, Spain. |
|
Conference news |
Oct 25, 2018 |
258 |
| Kadmon initiates Phase 2 KD025 trial in cGVHD. |
|
|
Oct 25, 2018 |
168 |
| Bristol-Myers doses first subject in Phase 1 trial using Halozyme's Enhanze. |
|
|
Oct 25, 2018 |
153 |
| Inovio announces results from Pennvax-GP Phase 1 study. |
|
|
Oct 25, 2018 |
131 |
| FibroGen presents two phase 3 study results of Roxadustat in CKD treatment. |
|
|
Oct 25, 2018 |
206 |
| Revlimid Demonstrated a Significant Improvement in Progression-Free Survival Compared with Observation in a Randomized Study in Patients with Smoldering Multiple Myeloma. |
|
|
Oct 25, 2018 |
181 |
| Japan : Eisai to present latest data on Alzheimers Disease/Dementia Pipeline at 11th Clinical Trials on Alzheimers Disease conference. |
|
Conference news |
Oct 25, 2018 |
383 |
| Switzerland : Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza. |
|
|
Oct 25, 2018 |
300 |
| United States : Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting. |
|
|
Oct 25, 2018 |
156 |
| Myovant Sciences: Enrollment complete in Phase 3 HERO trial of relugolix. |
|
|
Oct 24, 2018 |
128 |
| Neurotrope updates Phase 2 data of Alzheimer's candidate Bryostatin-1. |
|
|
Oct 24, 2018 |
199 |
| Genentech announces FDA approval of Xofluza for influenza. |
|
|
Oct 24, 2018 |
201 |
| Pancreatology Publishes Results of the PANOVA Phase 2 Pilot Trial in Advanced Pancreatic Cancer Suggesting Improved Survival of Patients Treated with Tumor Treating Fields. |
|
Clinical report |
Oct 24, 2018 |
544 |
| Provision Of Placebo And Minipress Drugs; Receipt, Packaging, Labeling, Storage, And Shipments Of Placebo Or Minipress For Clinical Trial "prazodream". |
|
|
Oct 24, 2018 |
181 |
| Lynparza phase III trial indicates decreased risk of disease progression or death in BRCA-mutated ovarian cancer patients. |
|
|
Oct 23, 2018 |
165 |
| Lynparza phase III trial indicates decreased risk of disease progression or death in BRCA-mutated ovarian cancer patients. |
|
|
Oct 23, 2018 |
161 |
| Solo-1 Phase III Trial Demonstrates Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70% in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer. |
|
|
Oct 23, 2018 |
143 |
| Deciphera initiates Phase 1b/2 clinical trial of rebastinib. |
|
|
Oct 23, 2018 |
173 |
| iCAD announces new clinical data on the Xoft Electronic Brachytherapy System. |
|
|
Oct 23, 2018 |
166 |
| Amcure Presents First Clinical Data for Lead Compound AMC303 at ESMO 2018 Congress. |
|
|
Oct 23, 2018 |
492 |
| Cantargia presents positive phase I trial CANFOUR clinical data with lead candidate CAN04 at ESMO 2018. |
|
|
Oct 22, 2018 |
296 |
| Cantargia presents positive phase I trial CANFOUR clinical data with lead candidate CAN04 at ESMO 2018. |
|
|
Oct 22, 2018 |
300 |
| Neon Therapeutics presents Phase 1b data on NEO-PV01 vaccine. |
|
|
Oct 22, 2018 |
188 |
| Oncolytics: Pelareorep more than doubles OS at recommended Phase 2 dose. |
|
|
Oct 22, 2018 |
218 |
| NuCana presents data from Phase 1 NUC-3373 study at ESMO. |
|
|
Oct 22, 2018 |
141 |
| Novocure announces publication of results of PANOVA phase 2 pilot trial. |
|
Clinical report |
Oct 22, 2018 |
380 |
| Zai Lab announces approval of Zejula for patients with relapsed ovarian cancer. |
|
|
Oct 22, 2018 |
237 |
| Flexion to present data from Phase 2 Zilretta study at ACR. |
|
|
Oct 22, 2018 |
206 |
| Ionis Pharmaceuticals presents Phase 1b/2 data of danvatirsen. |
|
|
Oct 22, 2018 |
194 |
| Ctn Data Statistics And Clinical Trial Support Center (dsc5). |
|
|
Oct 21, 2018 |
110 |
| Tesaro presents Phase 1 GARNET data of TSR-042 in MSI-H endometrial cancer. |
|
|
Oct 21, 2018 |
648 |
| Gilead, Galapagos NV announced data from Phase 3 FINCH2 trial of filgotinib. |
|
|
Oct 21, 2018 |
308 |
| G1 presents additional data from randomized Phase 2 trial in first-line SCLC. |
|
|
Oct 21, 2018 |
161 |
| United States : Dupixent (Dupilumab) Showed Positive Topline Results in Two Phase 3 Trials of Patients With Chronic Rhinosinusitis With Nasal Polyps. |
|
|
Oct 20, 2018 |
197 |
| France : Centre Georges Franois Leclerc Presents the Detailed Results of the First Two Stages of its Clinical Study in Lung Cancer at the EANM Congress. |
|
Clinical report |
Oct 20, 2018 |
172 |
| Spain : PharmaMar will present at ESMO results of the phase III CORAIL study with lurbinectedin in platinum-resistant Ovarian Cancer. |
|
|
Oct 20, 2018 |
169 |
| Innovent Biologics Inc treats first patient in phase I clinical trial of anti-CTLA-4 monoclonal antibody (IBI310). |
|
|
Oct 19, 2018 |
208 |
| Innovent Biologics Inc treats first patient in phase I clinical trial of anti-CTLA-4 monoclonal antibody (IBI310). |
|
|
Oct 19, 2018 |
204 |
| Clovis reports initial data from Phase 2 TRITON2 clinical trial of Rubraca. |
|
|
Oct 19, 2018 |
196 |
| Merrimack announces termination of Phase 2 SHERLOC study. |
|
Clinical report |
Oct 19, 2018 |
184 |
| Deciphera reports preliminary results of Phase 1 clinical study of DCC-2618. |
|
|
Oct 19, 2018 |
567 |
| Novartis: Phase II Geometry data shows ORR of 72%, 39.1% in study. |
|
|
Oct 19, 2018 |
214 |
| Incyte: Phase II Geometry data shows ORR of 72%, 39.1% in study. |
|
|
Oct 19, 2018 |
162 |
| Rodin Therapeutics Launches Clinical Trial of Neuroimaging Tool for Measurement of Synaptic Density. |
|
|
Oct 19, 2018 |
294 |
| Aelix Therapeutics, Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure. |
|
Clinical report |
Oct 19, 2018 |
450 |
| GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy. |
|
|
Oct 19, 2018 |
595 |
| Lab-on-skin: Lab-on-skin: A wearable medical device for improved clinical trial monitoring. |
|
|
Oct 19, 2018 |
326 |
| Imoted: Imoted platform built to improve clinical trial outcomes. |
|
|
Oct 19, 2018 |
420 |
| Mood: Feasibility study for the introduction into pre-clinical study domain of the first-of-a-kind multi organ on device (mood) technology. |
|
|
Oct 19, 2018 |
330 |
| Five Prime Therapeutics Initiates Patient Dosing in The Dose Exploration Cohort of Its Phase 1 Trial of Novel First-in-class B7-H4 Antibody FPA150. |
|
|
Oct 18, 2018 |
441 |
| Selecta Biosciences reports patient death in Phase 1 SEL-403 trial. |
|
|
Oct 18, 2018 |
401 |
| Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 11th Clinical Trials on Alzheimer's Disease Conference. |
|
Conference news |
Oct 18, 2018 |
1232 |
| First Patient Dosed in a Phase 1/2 Trial of Transgene's Oncolytic Virus TG6002 Administered Intravenously in Patients with Advanced Gastrointestinal Tumors. |
|
|
Oct 18, 2018 |
714 |
| Natera and Neon Therapeutics collaborate on cancer vaccine trial. |
|
|
Oct 18, 2018 |
127 |
| Natera, Neon Therapeutics announce clinical trial collaboration for NEO-PV-01. |
|
|
Oct 18, 2018 |
166 |
| Quotient Sciences Constructs Early-Phase Formulation and Manufacturing Facility in US. |
|
|
Oct 17, 2018 |
287 |
| Auris Medical reports Phase 1 clinical trial results for intranasal betahistine. |
|
|
Oct 17, 2018 |
140 |
| Aslan Pharmaceuticals enrolls first subject in Phase 1 study for ASLAN004. |
|
|
Oct 17, 2018 |
177 |
| Cellenkos to launch phase I clinical trial of CK0801 in patients with Guillain-BarrA(c) Syndrome (GBS) following US FDA clearance. |
|
|
Oct 17, 2018 |
250 |
| Alphamab Oncology announces US FDA approval for cancer therapy KN026. |
|
|
Oct 17, 2018 |
220 |
| CStone passes US FDA IND approval for PD-L1 antibody, CS1001. |
|
|
Oct 17, 2018 |
200 |
| Cellenkos to launch phase I clinical trial of CK0801 in patients with Guillain-BarrA(c) Syndrome (GBS) following US FDA clearance. |
|
|
Oct 17, 2018 |
246 |
| Alphamab Oncology announces US FDA approval for cancer therapy KN026. |
|
|
Oct 17, 2018 |
216 |
| CStone passes US FDA IND approval for PD-L1 antibody, CS1001. |
|
|
Oct 17, 2018 |
196 |
| ResTORbio announces additional data from RTB101 Phase 2b clinical trial. |
|
|
Oct 16, 2018 |
267 |
| Five Prime initiates patient dosing in dose exploration cohort of Phase 1 trial. |
|
|
Oct 16, 2018 |
258 |
| Celcuity, Puma Biotechnology and West Cancer Center to conduct Phase 2 trial. |
|
|
Oct 16, 2018 |
310 |
| United Kingdom : Supply of Investigational Medicinal Products for clinical trials in the event of a no-deal. |
|
|
Oct 16, 2018 |
305 |
| United States : Bipartisan Senators to NIH: Improve Racial, Ethnic Minority Representation in Clinical Trials. |
|
|
Oct 16, 2018 |
172 |
| United States : Cortez Masto, Colleagues Call on Nih to Improve Racial, Ethnic Minority Representation in Clinical Trials. |
|
|
Oct 16, 2018 |
218 |
| Mereo BioPharma Group completes patient enrolment for phase 2b clinical trial of BPS-804. |
|
|
Oct 16, 2018 |
158 |
| MaaT Pharma doses first patient in phase two clinical trial of MaaT013. |
|
Clinical report |
Oct 16, 2018 |
218 |
| Reflexion Health's first randomised controlled trial in virtual physical therapy excels against traditional approach. |
|
|
Oct 16, 2018 |
276 |
| Mereo BioPharma Group completes patient enrolment for phase 2b clinical trial of BPS-804. |
|
|
Oct 16, 2018 |
154 |
| MaaT Pharma doses first patient in phase two clinical trial of MaaT013. |
|
Clinical report |
Oct 16, 2018 |
214 |
| Reflexion Health's first randomised controlled trial in virtual physical therapy excels against traditional approach. |
|
|
Oct 16, 2018 |
272 |
| Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3. |
|
|
Oct 16, 2018 |
245 |
| Peptilogics Receives Australian Regulatory Approval to Initiate First-in-Human Safety Study for Therapeutic Peptide PLG0206. |
|
|
Oct 16, 2018 |
447 |
| Electronic 'Smart' Label for Clinical Trials. |
|
|
Oct 15, 2018 |
195 |
| Innovent to launch clinical trials of the combination therapy of IBI308 and IBI305 in patients with NSCLC & HCC in China. |
|
|
Oct 15, 2018 |
284 |
| Innovent to launch clinical trials of the combination therapy of IBI308 and IBI305 in patients with NSCLC & HCC in China. |
|
|
Oct 15, 2018 |
280 |
| Genentech says Phase III KATHERINE study met primary endpoint. |
|
|
Oct 15, 2018 |
202 |
| Arrowhead files for regulatory clearance to begin Phase 1 study of ARO-ANG3. |
|
|
Oct 15, 2018 |
165 |
| OncoSec initiates Phase 2 cllinical trial of Tavo with Merck's Keytruda. |
|
|
Oct 15, 2018 |
123 |
| Krystal Biotech announces interim results from Phase 1/2 trial of KB103. |
|
|
Oct 15, 2018 |
554 |
| Savara completes enrollment of IMPALA Phase 3 study. |
|
|
Oct 15, 2018 |
110 |
| Aimmune Therapeutics announces initiation of Phase 2 study of AR101. |
|
|
Oct 15, 2018 |
243 |
| United States : Arena Pharmaceuticals Presented Phase 2 Clinical Data for Etrasimod in Ulcerative Colitis at the American College of Gastroenterology Annual Meeting. |
|
|
Oct 15, 2018 |
150 |
| United States : Arena Pharmaceuticals Reports Positive Long-Term Data from the Ongoing Open-Label Extension of the Phase 2 Trial Evaluating Ralinepag for Treatment of Pulmonary Arterial Hypertension. |
|
Clinical report |
Oct 15, 2018 |
592 |
| Israel : Teva Presents 25-year Safety Data from Longest Continuous Trial of COPAXONE (glatiramer acetate injection) for the Treatment of Relapsing Forms of Multiple Sclerosis. |
|
|
Oct 15, 2018 |
389 |
| ISCO Doses Tenth Patient In Parkinson's Disease Clinical Trial. |
|
|
Oct 15, 2018 |
390 |
| ISCO Doses Tenth Patient In Parkinson's Disease Clinical Trial. |
|
|
Oct 15, 2018 |
389 |
| Cooper team helping battle rare genetic disorder. |
Vecchione, Anthony |
|
Oct 15, 2018 |
500 |
| Nofel Izz raising USD 30 mn to democratise clinical research and trials. |
|
|
Oct 12, 2018 |
834 |
| MaxCyte doses first patient in MCY-M11 US phase I dose-escalation clinical trial. |
|
|
Oct 12, 2018 |
208 |
| MaxCyte doses first patient in MCY-M11 US phase I dose-escalation clinical trial. |
|
|
Oct 12, 2018 |
204 |
| I-Mab Biopharma treats the first ulcerative colitis patient in China under its phase II clinical trial of TJ301. |
|
|
Oct 12, 2018 |
235 |
| First Patient Dosed in Phase 2 Clinical Trial of MaaT Pharma Lead Product MaaT013, a First-in-class Biotherapeutic to Treat Acute GvHD. |
|
|
Oct 12, 2018 |
450 |
| BeiGene presents updated Phase 1 data on zanubrutinib. |
|
|
Oct 12, 2018 |
201 |
| Singapore : Winners of Newtrition Asia Research Grant 2018 to address pressing health concerns in Asia with new clinical studies. |
|
Clinical report |
Oct 12, 2018 |
585 |
| Clinical Research Administrative Management Service. |
|
|
Oct 12, 2018 |
109 |
| International Clinical Trial Utilises Personal Genome Diagnostics' Liquid Biopsy Assay to Enroll Patients based on POLE/POLD1 status as a Predictor of Response to Immunotherapy. |
|
|
Oct 11, 2018 |
271 |
| First clinical trial of Alzheimer's disease treatment starts at The National Institute for Health Research University College London Hospitals Clinical Research Facility. |
|
|
Oct 11, 2018 |
212 |
| First clinical trial of Alzheimer's disease treatment starts at The National Institute for Health Research University College London Hospitals Clinical Research Facility. |
|
|
Oct 11, 2018 |
208 |
| Progenics advances prostrate cancer treatment to phase 2 after FDA discussions. |
|
|
Oct 11, 2018 |
226 |
| BioPharmX initiates Phase 2b trial of BPX-04 for rosacea. |
|
|
Oct 11, 2018 |
120 |
| Australia : Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for LOXL2 Inhibitor Compound. |
|
|
Oct 11, 2018 |
252 |
| Crispr Therapeutics, Vertex announce FDA lifts hold for CTX001, accepts IND. |
|
|
Oct 10, 2018 |
127 |
| Constellation Pharmaceuticals expands Phase 2 study of CPI-0610. |
|
|
Oct 10, 2018 |
258 |
| General Committee to review Sisi's objections to clinical trials draft law. |
|
|
Oct 10, 2018 |
556 |
| NeuroVive Pharmaceutical announces receipt of KL1333 clinical trial regulatory approval from MHRA in UK. |
|
|
Oct 10, 2018 |
238 |
| NeuroVive Pharmaceutical announces receipt of KL1333 clinical trial regulatory approval from MHRA in UK. |
|
|
Oct 10, 2018 |
234 |
| Symphony Clinical Research earns recertification. |
|
|
Oct 10, 2018 |
178 |
| TapImmune receives DoD grant for TPIV110 phase 2 study to treat breast cancer. |
|
|
Oct 10, 2018 |
199 |
| Motus GI presented 'positive' clinical data on Pure-Vu System. |
|
Clinical report |
Oct 10, 2018 |
246 |
| Revolution Medicines: First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors. |
|
|
Oct 10, 2018 |
552 |
| Yisheng Biopharma wins China FDA approval to commence PIKA rabies vaccine clinical study in Asia. |
|
|
Oct 9, 2018 |
206 |
| Yisheng Biopharma wins China FDA approval to commence PIKA rabies vaccine clinical study in Asia. |
|
|
Oct 9, 2018 |
202 |
| Cavion Touts Promising Phase 2 Data for Essential Tremor in T-CALM Proof-of-Concept Study. |
|
|
Oct 9, 2018 |
863 |
| G1 Therapeutics announces new data from Phase 2 trilaciclib trial at ESMO. |
|
|
Oct 9, 2018 |
120 |
| Bellerophon provides update on Phase 2b iNO-PF study. |
|
Clinical report |
Oct 9, 2018 |
254 |
| Sermonix Pharmaceuticals launches Phase 2 trial to evaluate oral lasofoxifene. |
|
Clinical report |
Oct 9, 2018 |
123 |
| Nymox: Gleason grade progression reduced by 81% in FT Phase IIb trial. |
|
|
Oct 9, 2018 |
310 |
| Parliament to review controversial clinical trials draft law. |
|
|
Oct 9, 2018 |
156 |
| Exelixis Initiates Phase 3 Pivotal Trial of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy. |
|
|
Oct 9, 2018 |
537 |
| Coordination Pharmaceuticals Inc wins US FDA approval to study the first NCP-based product CPI-100 in clinical trials. |
|
|
Oct 8, 2018 |
219 |
| Coordination Pharmaceuticals Inc wins US FDA approval to study the first NCP-based product CPI-100 in clinical trials. |
|
|
Oct 8, 2018 |
215 |
| Audentes Therapeutics Touts New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, at 23rd International Annual Congress of the World Muscle Society. |
|
|
Oct 8, 2018 |
751 |
| BerGenBio Enters Second Stage of Phase II Trial with Selective AXL Inhibitor bemcentinib in Combination with US Merck's Keytruda in Patients with Advanced NSCLC. |
|
|
Oct 8, 2018 |
587 |
| Bausch Health's BRYHALI Lotion, 0.01% receives tentative FDA approval. |
|
|
Oct 8, 2018 |
119 |
| BioXcel Therapeutics submits IND application for BXCL701. |
|
|
Oct 8, 2018 |
156 |
| Cocrystal Pharma announces clinical trial agreement for CC-31244. |
|
|
Oct 8, 2018 |
204 |
| FDA puts Affimed N.V.'s AFM11 phase 1 program on hold following death of patient. |
|
|
Oct 8, 2018 |
212 |
| Affimed N.V. places AFM11 Phase 1 program on clinical hold. |
|
|
Oct 8, 2018 |
206 |
| Consumables For Hematological And Clinical Trials. |
|
|
Oct 8, 2018 |
161 |
| Blueprint Medicines Releases Updated Data from Phase 1 ARROW Clinical Trial of BLU-667 in Advanced RET-Altered Medullary and Papillary Thyroid Cancers. |
|
|
Oct 8, 2018 |
1406 |
| FDA Grants Coordination Pharmaceuticals IND Approval for CPI-100, a Novel Antitumor Nanomedicine. |
|
|
Oct 8, 2018 |
145 |
| Web-based service targets clinical trial sponsors. |
|
|
Oct 8, 2018 |
695 |
| Blueprint Medicines announces updated data from Phase 1 ARROW clinical trial. |
|
|
Oct 7, 2018 |
595 |
| United States : Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma. |
|
Financial report |
Oct 6, 2018 |
716 |
| Ophthotech Completes Patient Recruitment As Planned for its Phase 2b Clinical Trial of Zimura Monotherapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. |
|
|
Oct 5, 2018 |
518 |
| Alnylam Pharmaceuticals files clinical trial authorisation application to start phase 1/2 trial of ALN-AAT02. |
|
|
Oct 5, 2018 |
246 |
| Spinal Singularity earns USD1.5m NIH Phase II SBIR Grant. |
|
|
Oct 5, 2018 |
185 |
| Alnylam Pharmaceuticals files clinical trial authorisation application to start phase 1/2 trial of ALN-AAT02. |
|
|
Oct 5, 2018 |
242 |
| Frequency Therapeutics Completes Enrollment in Single Dose Safety Trial to Evaluate FX-322, a First-in-Class Drug Candidate for Hearing Restoration. |
|
|
Oct 5, 2018 |
560 |
| Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1. |
|
Clinical report |
Oct 5, 2018 |
1181 |
| Merck Releases Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating Delstrigo for the Treatment of HIV-1 in Treatment-NaA-ve Patients. |
|
|
Oct 5, 2018 |
798 |
| Allergan launches two global clinical research programs for brazikumab. |
|
|
Oct 5, 2018 |
143 |
| XBiotech completes enrollment of phase 2 bermekimab study. |
|
Clinical report |
Oct 5, 2018 |
112 |
| PureTech's Vedanta reports successful Phase 1a/1b trial of recurrent C. difficile treatment. |
|
|
Oct 4, 2018 |
205 |
| PureTech's Vedanta reports successful Phase 1a/1b trial of recurrent C. difficile treatment. |
|
|
Oct 4, 2018 |
201 |
| Eli Lilly presents phase 2b trial data of dual GIP, GLP-1 receptor agonist. |
|
|
Oct 4, 2018 |
366 |
| Alnylam reports updated 'positive' results from Phase 1/2 study of lumasiran. |
|
|
Oct 4, 2018 |
443 |
| Viking Therapeutics: VK2809 Phase 2 study results selected for presentation. |
|
Report |
Oct 4, 2018 |
172 |
| Ophthotech completes patient recruitment for Phase 2b clinical trial of Zimura. |
|
|
Oct 4, 2018 |
105 |
| Regenxbio completes dosing fourth cohort in Phase 1 trial of wet AMD candidate. |
|
|
Oct 4, 2018 |
126 |
| Adamas Pharmaceuticals publishes Phase 3 Gocovri data. |
|
|
Oct 4, 2018 |
158 |
| Centogene, Denali Therapeutics Team to Recruit LRRK2 Patients for Clinical Trials. |
|
|
Oct 4, 2018 |
289 |
| Alnylam Submits Clinical Trial Authorization Application for ALN-AAT02, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease. |
|
|
Oct 4, 2018 |
437 |
| Vedanta Biosciences Touts Phase 1a/1b Data Demonstrating Safety, Tolerability, and Proof of Mechanism for Lead, Rationally Defined Bacterial Consortium Product Candidate, VE303. |
|
|
Oct 4, 2018 |
804 |
| Processa Pharmaceuticals wins US FDA clearance to start Phase 2 clinical development of PCS-499 in patients with Necrobiosis Lipoidica. |
|
|
Oct 3, 2018 |
207 |
| Processa Pharmaceuticals wins US FDA clearance to start Phase 2 clinical development of PCS-499 in patients with Necrobiosis Lipoidica. |
|
|
Oct 3, 2018 |
203 |
| BioPorto announces initiation of retrospective clinical study with The NGAL Test for children under the age of 18. |
|
Clinical report |
Oct 3, 2018 |
308 |
| BioPorto announces initiation of retrospective clinical study with The NGAL Test for children under the age of 18. |
|
Clinical report |
Oct 3, 2018 |
304 |
| Sisi objects to some articles of medical and clinical research draft law. |
|
|
Oct 3, 2018 |
772 |
| ObsEva reports additional 'positive' Phase 3 results of IMPLANT 2 trial. |
|
|
Oct 3, 2018 |
211 |
| Al-Sisi expresses objection regarding some articles of clinical trials' draft law. |
|
|
Oct 3, 2018 |
311 |
| Inotrem demonstrates safety and tolerability of nangibotide in phase IIa study. |
|
|
Oct 2, 2018 |
159 |
| Inotrem demonstrates safety and tolerability of nangibotide in phase IIa study. |
|
|
Oct 2, 2018 |
155 |
| Clementia Pharmaceuticals initiates Phase 1 clinical trial of palovarotene. |
|
|
Oct 2, 2018 |
123 |
| Rexahn presents preliminary data from ongoing Phase 2a trial of RX-3117. |
|
|
Oct 2, 2018 |
255 |
| Independent Data Monitoring Committee Recommends Continuing Inclisiran Phase III Trials. |
|
|
Oct 2, 2018 |
347 |
| Aveo Oncology Starts Topline Analysis of Phase 3 TIVO-3 Trial. |
|
|
Oct 2, 2018 |
800 |
| Seattle Genetics, Takeda Tout Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating Adcetris in Frontline CD30-Expressing Peripheral T-Cell Lymphoma. |
|
|
Oct 2, 2018 |
1050 |
| Innovent passes US FDA approval to initiate clinical trials of Anti-CD47 Monoclonal Antibody IBI-188. |
|
|
Oct 1, 2018 |
237 |
| Innovent passes US FDA approval to initiate clinical trials of Anti-CD47 Monoclonal Antibody IBI-188. |
|
|
Oct 1, 2018 |
233 |
| TransThera Biosciences wins US FDA IND approval for initiating clinical trials of TT-00420 targeting TNBC. |
|
|
Oct 1, 2018 |
162 |
| TransThera Biosciences wins US FDA IND approval for initiating clinical trials of TT-00420 targeting TNBC. |
|
|
Oct 1, 2018 |
158 |
| Viking Therapeutics says Phase 2 study of VK5211 achieves primary endpoint. |
|
|
Oct 1, 2018 |
550 |
